专业监测看板

Single Blinded First CMC Osteoarthritis Treatment

药物 / 成分：Platelet Concentrate、Corticosteroid injection、Normal Saline

登记的停止原因（原文）：Due to lack of enrollment, challenging follow-up, and lack of funding.

MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma

药物 / 成分：Confocal Microscopy、Dermoscopy、Imaging Procedure、Lidocaine

登记的停止原因（原文）：The study did not meet its accrual goals due to the departure of study personnel. Study team opted for a study closure due to loss of key personnel.

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

药物 / 成分：Inlexisertib、Trametinib、Binimetinib、Sotorasib

登记的停止原因（原文）：Trial terminated due to business decision, not based on any safety or efficacy concerns.

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

药物 / 成分：Iclepertin

Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors

药物 / 成分：BNT142

登记的停止原因（原文）：Sponsor decision

TPN-101 in Aicardi-Goutières Syndrome (AGS)

药物 / 成分：TPN-101

登记的停止原因（原文）：Business decision

Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

药物 / 成分：Estradiol

登记的停止原因（原文）：Trial terminated by Sponsor.

Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy

药物 / 成分：VGT-309

登记的停止原因（原文）：The drug supply expired and the sponsor is unable to provide an updated supply.

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

药物 / 成分：MGN1703、Ipilimumab

登记的停止原因（原文）：\<75% participation

Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)

药物 / 成分：Liposomal Cyclosporine A 5 mg、Liposomal Cyclosporine A 10 mg

登记的停止原因（原文）：Study was terminated for business reasons. The earlier study end is not related to any safety concerns or data issues identified at any site or within the overall study data collected to date.

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

药物 / 成分：Methadone、Buprenorphine/naloxone、XR-Naltrexone

登记的停止原因（原文）：Funding not renewed

A Study of Belcesiran in Patients With AATLD

药物 / 成分：Belcesiran、Placebo、Belcesiran、Placebo

登记的停止原因（原文）：Development project was discontinued

Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant

药物 / 成分：Ruxolitinib

登记的停止原因（原文）：Study closed due to slow enrollment.

Deucravacitinib for the Treatment of Palmoplantar Pustulosis

药物 / 成分：Deucravacitinib

登记的停止原因（原文）：Sponsor terminated funding

Study of Acamprosate in Driving Under the Influence (DUI) Court Participants

药物 / 成分：Acamprosate

登记的停止原因（原文）：Recruitment barriers.

ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy

药物 / 成分：CLEVUDINE + TENOFOVIR PLACEBO、CLEVUDINE IN ASSOCIATION TENOFOVIR、TENOFOVIR + CLEVUDINE PLACEBO

登记的停止原因（原文）：safety aspects

Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer

药物 / 成分：Olaparib、Placebo

登记的停止原因（原文）：study design, change of standard of care, enrollment difficulties

Adductor Canal Block

药物 / 成分：Ropivacaine injection、Saline Injection、Total Knee Arthroplasty

登记的停止原因（原文）：Principal Investigator left the lead site. New Principal Investigator was not selected. Project was discontinued.

Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome

药物 / 成分：Gentulizumab

登记的停止原因（原文）：Adjusted the product development strategy.

Evaluate the Efficacy and Safety of Different Doses of Edaravone Dexborneol Concentrated Solution for Injection Combined With Conventional Medical Therapy in the Treatment of Patients With Cerebral Hemorrhage

药物 / 成分：Sanbexin IV/Placebo

登记的停止原因（原文）：This study was terminated after completing the first dose level of Sanbenxin 37.5 mg due to the decision made by the sponsor that a new clinical development program for the new form of sublingual tablets would replace the existing plan.